lapatinib has been researched along with jnj-7706621 in 7 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (jnj-7706621) | Trials (jnj-7706621) | Recent Studies (post-2010) (jnj-7706621) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 40 | 0 | 32 |
| Protein | Taxonomy | lapatinib (IC50) | jnj-7706621 (IC50) |
|---|---|---|---|
| [tau protein] kinase | Oryctolagus cuniculus (rabbit) | 0.0849 | |
| Vascular endothelial growth factor receptor 2 | Rattus norvegicus (Norway rat) | 0.0849 | |
| Aurora kinase A | Homo sapiens (human) | 0.011 | |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 1.4805 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.0062 | |
| cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) | 0.0849 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0849 | |
| Insulin receptor | Homo sapiens (human) | 0.0849 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.0537 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.0849 | |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Rattus norvegicus (Norway rat) | 0.0849 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.11 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.0652 | |
| Cyclin-A2 | Homo sapiens (human) | 0.0731 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.1042 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.11 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0575 | |
| G1/S-specific cyclin-D1 | Mus musculus (house mouse) | 0.0849 | |
| Cyclin-dependent kinase 4 | Mus musculus (house mouse) | 0.0849 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.13 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.041 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.041 | |
| Mitogen-activated protein kinase 1 | Rattus norvegicus (Norway rat) | 0.0849 | |
| Cyclin-A1 | Homo sapiens (human) | 0.002 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.0062 | |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | 0.058 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.0126 | |
| Casein kinase I isoform delta | Rattus norvegicus (Norway rat) | 0.0849 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.0062 | |
| Aurora kinase B | Homo sapiens (human) | 0.0095 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Russu, WA; Shallal, HM | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
7 other study(ies) available for lapatinib and jnj-7706621
| Article | Year |
|---|---|
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |